Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 6/20 | 0.63 |
| ▸ | MKNK2 | Q9HBH9 | 6/20 | 0.63 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.59 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.59 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.58 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.58 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.58 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.58 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.57 |
| ▸ | XDH | P47989 | 1/20 | 0.51 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.51 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.50 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.49 |
| ▸ | TNKS | O95271 | 1/20 | 0.49 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.49 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.49 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.49 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28281436 | 0.86 | SIRT2 (0.76) | MKNK1MKNK2PARP10SIRT2SIRT3 | |
| SCHEMBL2488476 | 0.86 | MKNK1 (0.77) | MKNK1MKNK2CYP11B2CYP11B1SIRT2 | |
| SCHEMBL3711432 | 0.83 | HDAC8 (0.56) | MKNK1MKNK2XDHSLC22A12 | |
| SCHEMBL3713278 | 0.83 | CYP11B1 (0.64) | MKNK1MKNK2CYP11B2CYP11B1MAP4K4 | |
| SCHEMBL1758530 | 0.82 | MAP4K4 (0.83) | MKNK1MKNK2CYP11B2CYP11B1PARP10 | |
| SCHEMBL29870407 | 0.82 | MAP4K4 (0.83) | MKNK1MKNK2CYP11B2CYP11B1PARP10 | |
| SCHEMBL27986242 | 0.80 | MKNK1 (0.87) | MKNK1MKNK2CYP11B2CYP11B1MAP4K4 | |
| SCHEMBL1758325 | 0.79 | CYP11B2 (0.70) | MKNK1MKNK2CYP11B2CYP11B1SIRT2 | |
| SCHEMBL13741926 | 0.79 | SCN2A (0.55) | XDHSLC22A12 | |
| SCHEMBL6754398 | 0.79 | MKNK1 (0.67) | MKNK1MKNK2CYP11B2CYP11B1SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105549-B2 | Aryl substituted pyridines and the use thereof | EURO-CELTIQUE S.A. (LU) | 2006-09-12 | — | — | US | claimed |
| US-20030055088-A1 | Aryl substituted pyridines and the use thereof | EURO-CELTIQUE S.A. | 2003-03-20 | — | — | US | claimed |
| US-7943643-B2 | Aryl substituted pyridines and the use thereof | PURDUE PHARMA L.P. (US) | 2011-05-17 | — | — | US | disclosed |
| US-20100048626-A1 | Aryl Substituted Pyridines and the Use Thereof | PURDUE PHARMA L.P. | 2010-02-25 | — | — | US | disclosed |
| US-20100048626-A1 | Aryl Substituted Pyridines and the Use Thereof | PURDUE PHARMA L.P. | 2010-02-25 | — | — | US | disclosed |
| US-7579367-B2 | Aryl substituted pyridines and the use thereof | PURDUE PHARMA L.P. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20080194627-A9 | Aryl substituted pyridines and the use thereof | EURO-CELTIQUE S.A. (LU) | 2008-08-14 | — | — | US | disclosed |
| US-20070010554-A1 | Aryl substituted pyridines and the use thereof | EURO-CELTIQUE S.A. (LU) | 2007-01-11 | — | — | US | disclosed |
| US-7105549-B2 | Aryl substituted pyridines and the use thereof | EURO-CELTIQUE S.A. (LU) | 2006-09-12 | — | — | US | disclosed |
| EP-1432419-A1 | ARYL SUBSTITUTED PYRIDINECARBOXAMIDES AND THEIR USE AS SODIUM CHANNEL BLOCKERS | Euro-Celtique S.A. (LU) | 2004-06-30 | — | — | EP | disclosed |
| US-20030055088-A1 | Aryl substituted pyridines and the use thereof | EURO-CELTIQUE S.A. | 2003-03-20 | — | — | US | disclosed |
| WO-2003022276-A1 | ARYL SUBSTITUTED PYRIDINECARBOXAMIDES AND THEIR USE AS SODIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194627-A9 | Aryl substituted pyridines and the use thereof | CACNA1S, CACNA1E, CACNA1C | MKNK1 4472/4885MKNK2 4569/4885CYP11B2 1341/4885 |
| US-20100048626-A1 | Aryl Substituted Pyridines and the Use Thereof | CACNA1S, CACNA1E, CACNA1C | MKNK1 4532/4885MKNK2 4591/4885CYP11B2 1486/4885 |
| US-20030055088-A1 | Aryl substituted pyridines and the use thereof | CACNA1S, CACNA1E, CACNA1D | MKNK1 4334/4885MKNK2 4509/4885CYP11B2 1609/4885 |
| US-20070010554-A1 | Aryl substituted pyridines and the use thereof | CACNA1S, CACNA1E, CACNA1C | MKNK1 4472/4885MKNK2 4569/4885CYP11B2 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.